The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model

Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2013, Pages 314-325

  Zhao, Liang ^a   Ji, Ping ^a   Li, Zhihong ^a   Roy, Partha ^a   Sahajwalla, Chandrahas G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Absorption; Bioavailability; Monoclonal antibody; Pharmacokinetics; Physiologically based pharmacokinetic model

Indexed keywords

FC RECEPTOR; MONOCLONAL ANTIBODY; OMALIZUMAB;

ARTICLE; CIRCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; HUMAN; MATHEMATICAL MODEL; PROTEIN DEGRADATION; SENSITIVITY ANALYSIS; SIMULATION;

ABSORPTION; ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MODELS, BIOLOGICAL;

EID: 84877851717     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.4     Document Type: Article

References (43)

1. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev. 2006; 58(5-6):686-706.
2. ReillyRM, Domingo R, Sandhu J. Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet. 1997;32(4):313-323.
3. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7(2):167-169.
4. Tang L, Meibohm B. Pharmacokinetics of peptides and proteins. Pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. Bernd Meibohm (Editor). Weinheim, Germany: WILEY-VCH Verlag GmbH & Co. KGaA; ISBN: 978-3-527-31408-9. 2007; Chapter 2: p 15-23.
5. Kagan L, Gershkovich P, MendelmanA, Amsili S, Ezov N, Hoffman A. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm. 2007; 67(3):759-765.
6. Charman SA, Segrave AM, Edwards GA, Porter CJ. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. J Pharm Sci. 2000;89(2): 168-177.
7. Laplanche R, Meno-Tetang GM, Kawai R. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J Pharmacokinet Pharmacodyn. 2007;34(3):373-400.
8. Kristensen NR, Madsen H, Ingwersen SH. Using stochastic differential equations for PK/PD model development. J Pharmacokinet Pharmacodyn. 2005;32(1):109-141.
9. Beck BD, Mattuck RL, Bowers TS, Cohen JT, O'Flaherty E. The development of a stochastic physiologically-based pharmacokinetic model for lead. Sci Total Environ. 2001;274(1-3):9-15.
10. Willmann S, Höhn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401-431.
11. Lánský P. A stochastic model for circulatory transport in pharmacokinetics. Math Biosci. 1996;132(2):141-167.
12. Matis JH, Kiffe TR, Matis TI, Stevenson DE. Nonlinear stochastic modeling of aphid population growth. Math Biosci. 2005;198 (2):148-168.
13. Jang SH, Wientjes MG, Au JL. Determinants of paclitaxel uptake, accumulation and retention in solid tumors Investigational New Drugs. 2001;19(2):113-123.
14. Zhao L. New developments in using stochastic recipe for multicompartment model: inter-compartment traveling route, residence time, and exponential convolution expansion. Math Biosci Eng. 2009;6(3):663-682.
15. Zhao L, Li N, Yang H. A new stochastic approach to multicompartment pharmacokinetic models: probability of traveling route and distribution of residence time in linear and nonlinear systems. J Pharmacokinet Pharmacodyn. 2011;38(1):83-104.
16. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34 (5):687-709.
17. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 1994;54(6):1517-1528.
18. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55(20):4611-4622.
19. Friedrich SW, Lin SC, Stoll BR, Baxter LT, Munn LL, Jain RK. Antibody-directed effector cell therapy of tumors: analysis and optimization using a physiologically based pharmacokinetic model. Neoplasia. 2002;4(5):449-463.
20. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ III. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther. 2006;5(6):1550-1558.
21. Ferl GZ,WuAM, DiStefano JJ III. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005;33(11):1640-1652.
22. Gessner JE, Heiken H, Tamm A, Schmidt RE. The IgG Fc receptor family. Ann Hematol. 1998;76(6):231-248.
23. Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 2005;15:5-9.
24. Flessner MF, Lofthouse J, Zakaria el-R. In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. Am J Physiol. 1997;273(6 Pt 2):H2783-H2793.
25. Urva SR, Yang VC, Balthasar JP. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci. 2010;99(3):1582-1600.
26. Zhou J, Johnson JE, Ghetie V, Ober RJ, Ward ES. Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol. 2003;332(4):901-913.
27. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition ofmonoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol. 2008;8(3):401-413.
28. McLennan DN, Porter CJ, Edwards GA, Brumm M, Martin SW, Charman SA. Pharmacokinetic model to describe the lymphatic absorption of r-metHu-leptin after subcutaneous injection to sheep. Pharm Res. 2003;20(8):1156-1162.
29. Garg A, Balthasar JP. PhD Thesis. Department of Pharmaceutical Science SUNY Buffalo. 2007; Chapter 3: 71-111.
30. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanismbased binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007; 63(5):548-561.
31. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62:779-786.
32. Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006;23(6): 1275-1284.
33. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2 metastatic breast cancer. Cancer Chemother Pharmacol. 2005;56(4):361-369.
34. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet. 2011;50(4):215-227.
35. Turner-Warwick RT. Intravital techniques for the demonstration of lymphatics. Ann R Coll Surg Engl. 1959;24(2):101-109.
36. de Veer M, Kemp J, Chatelier J, Elhay MJ, Meeusen EN. Modulation of soluble and particulate antigen transport in afferent lymph by monophosphoryl lipid A. Immunol Cell Biol. 2012;90(4):404-410. DOI: 10.1038/icb.2011.53
37. McMaster PD. Changes in the cutaneous lymphatics of human beings and the lymph flow under normal and pathological conditions. J Exp Med. 1937;65(3):347-372.
38. Ikomi F, Hunt J, Hanna G, Schmid-Schönbein GW. Interstitial fluid, plasma protein, colloid, and leukocyte uptake into initial lymphatics. J Appl Physiol. 1996;81(5):2060-2067.
39. Swartz MA, Berk DA, Jain RK. Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. Am J Physiol. 1996;270(1 Pt 2):H324-H329.
40. Uren RF, Thompson JF, Howman-Giles RB. Lymphatic drainage of the skin and breast-locating sentinel nodes. Singapore: Harwood Academic Publishers; 1999;15:17-49, 66.
41. Uren RF, Howman-Giles R, Thompson JF, et al. Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Res. 1994;4(6):395-399.
42. Pedersen B, Kristensen K. Evaluation of methods for sizing of colloidal radiopharmaceuticals. Eur J Nucl Med. 1981;6(11):521-526.
43. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84: 548-558.